summari due report result updat
ep estim slightli ahead consensu forecast
may reflect differ assumpt
magnitud gain sale asp confid
estim sale estim organ in-lin
consensu estim analysi im data suggest strength
us pharmaceut product see pharma
tracker start page increas forecast
modestli us pharmaceut busi aggreg
uncertainti remain impact discounting/reb
competit product like xarelto stelara seen price
adjust recent quarter analysi nielsen data
suggest slight growth acceler us consum
consist model year expect maintain
organ sale growth guidanc would rule rais due
slightli reduc gener headwind could see ep
guidanc rais base slightli reduc fx headwind
current forecast organ sale growth guidanc
report ep guidanc
see modest upsid us pharma sale consum
growth acceler forecast total sale
includ fx headwind organ sale
growth repres deceler due
tougher comp pharma medic devic analysi
im sales/rx trend indic potenti upsid thu
increas forecast net basi consum
nielsen data show slight acceler us consum growth
direct consist
forecast organ us consum sale growth
flattish due easier comp
see potenti modest guidanc rais guid
organ sale growth report ep
midpoint base im analysi
jnj recent track record could see manag rais
underli sale growth modestli guidanc year growth
guidanc rais addit math
suggest fx headwind may lower
guidanc year could add cent
bottom-lin continu anticip medic devic
consum sale growth grow in-lin slightli
market pharma sale growth also fall
market improv back half forecast sale
organ report ep
compar consensu forecast respect
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
compani data secur llc estim reuter
ep estim slightli ahead forecast forecast ep ahead
consensu estim consensu forecast like reflect least part estim
net incom reflect gain asp divestitur close earli
said net incom guidanc reflect asp gain
given exact amount total revenu forecast in-lin consensu expect
us pharma trend slightli expect consum in-lin due
report result estim total sale organ ep vs
consensu respect im analysi show potenti modest upsid rel
expect us pharma sale net basi part due slower expect delay gener
competit impact estim organ pharma sale growth vs
deceler reflect tougher yr/yr comp greater impact us biosimilar gener
competit consum estim organ growth due easier
comp analysi nielsen data point acceler us consum growth
direct consist forecast organ us growth vs flattish
due easier comp continu relaunch babi care brand ou could help consum
perform medic devic model organ sale growth due
tougher comp contact len stock benefit small neg sell day impact ou
forecast assum fx headwind rel unchang vs month ago
im data suggest slight upsid perform key us drug base im
analysi rais us sale forecast zytiga tremfya tracleer simponi/aria
aggreg partli off-set lower sale estim remicad invokana total
addit chang invega sustenna/trinza forecast well extrapol im
sale due im sale well recent trend thu may reflect im methodology/data
chang rather true under-perform also note forecast us xarelto stelara
sale within extrapol im sale rang prior period price adjust
product recent quarter make us bit cautiou impact rebating/discount
product given competit environ forecast us pharmaceut sale
nearli yr/yr declin compar organ growth adjust prior period price
adjust note repres toughest comp jnj us pharma busi
prior year growth detail product tracker analysi start page
us drug price increas earli rais price across much us drug portfolio
similar magnitud price increas similar lower compani histor
price action price increas rang darzalex procrit xarelto
invega sustenna hand older alreadi generic product like levaquin ditropan xl
expect much price increas net discounts/rebates/fe saw
price increas histor rais price per year accord us
transpar report net us drug price fell last year compar low
mid-singl digit increas list price discount rebat fee us drug rose
compar increas
organ growth ex-fx compani report secur llc estim organ growth adjust fx acquisitions/divestitur sell day prior price adjust pharma venezuela anima exit pharma overal growth adjust remicad rebat ex-adjust organ growth pharma overal cardiovascular cerenovu neurovascular intervent solut start diabet adjust anima exit impact amo acqusit includ ex-fx growth rate atln acquisit includ ex-fx growth rate key busi segment johnson johnson
consum growth expect acceler due easier comp jnj ww consum sale
growth slow organ manag larg attribut
broad market soft despit jnj-specif share gain sever key segment expect ww
consum organ sale growth acceler due easier yr/yr comp consum
growth due us inventori destock ahead babi care relaunch addit growth
somewhat hurt ou destock ahead babi care relaunch new market believ
start rebound relaunch analysi aggreg nielsen data
also suggest slight growth acceler would
forecast figur nielsen data appear trend direct in-lin report us
consum sale growth time notabl quarterli variat figur ww basi
forecast consum sale organ growth includ us sale
nielsen sale base aggreg data
nielsen sale base aggreg data
see possibl sale growth guidanc rais guid organ sale
growth ex-fx acquisit divestitur includ headwind gener
biosimilar competit analysi im suggest biosimilar headwind like
acceler sinc rate gener zytiga tracleer eros appear benign
expect addit im trend show continu strong perform number key us
drug net-net take account jnj recent histori rais guidanc see possibl
slight upsid top-lin guidanc specif rais underli sale growth
guidanc addit slower expect biosimilar/gener
eros contribut sale growth guidanc rais quarter
caveat limit visibl busi outsid us pharma/consum furthermor
ceo gorski commentari recent investor confer compani expect growth
pharma busi declin slightli year encourag given
tougher headwind face pharma model assum jnj consum medic
devic busi grow slightli in-lin market pharma sale grow
market net organ sale growth report sale yr/yr declin
fx headwind like eas somewhat recent fx analysi point slight eas currenc
headwind year vs guidanc translat potenti ep impact
vs guidanc math fx headwind approxim vs
declin becom essenti neutral updat report sale forecast
reflect chang made chang ep forecast
potenti modest upward revis ep guidanc call guid
report ep guidanc growth midpoint rang guidanc includ
fx headwind oper ep guidanc growth even without
increas underli sale growth outlook could see modest increas report ep
guidanc given slight eas fx headwind note alreadi narrow ep guidanc rang
histor happen unclear compani narrow
rang time model continu assum complet share buy-back
program year complet end could contribut annual
earn accret forecast report ep yr/yr growth in-lin
continu expect acceler top-lin growth forecast organ sale
growth estim acceler growth outlook larg reflect
improv sale growth estim year next year
reflect tough comp primarili due gener zytiga headwind lesser extent
gener tracleer biosimilar procrit impact look expect jnj pharma sale growth
acceler return market growth consist manag public commentari
pharma would outpac market growth addit divestitur slower
growth busi like asp medic devic acquisit faster busi like dr ci labo
consum continu improv sale growth busi well go
estmkt compani report secur llc estim organ growth report ex-fx adjust sell day differ venezuela impact prior period price johnson johnson
lower us remicad sale forecast reduc us remicad ex-export sale
estim yr/yr declin compar yr/yr forecast
adjust reflect qtd im sale trend although note trend seen greater quarterli
fluctuat sinc start biosimilar competit specif extrapol im sale show
declin remicad yr/yr vs estim report us sale declin refer quarterli im
sale declin mid-singl digit report us sale fell
biosimilar remicad penetr inch slowli im sale show biosimilar remicad sale
start inch seemingli stall im sale total oct
compar jan may figur monthli sale second
biosimilar launch nearli year ago tripl
recent sale pfe/celltrion first-to-market biosimilar littl chang
recent meanwhil trail averag remicad im sale remain
rang even report sale declin due increas rebat discount pfe/celltrion
inflectra account biosimilar remicad im sale
biosimilar procrit uptak remain ahead biosimilar remicad earli day pfe biosimilar
procrit retacrit launch sale ramp to-dat appear move faster initi
biosimilar remicad launch specif im sale show retacrit sale nearli may
februari decemb time jnj procrit im sale fallen
respect month retacrit market
uptak ahead inflectra initi uptak forecast us procrit sale
yr/yr improv compar due tougher yr/yr comp forecast
seem reason base extrapol im sale
spravato balversa launch underway receiv fda approv spravato treatment
resist depress balversa bladder cancer earlier year spravato distribut limit
physician must certifi prescrib product data limit given earli natur launch
accord im spravato balversa im sale total nearli may compar
forecast us sale spravato balversa take account launch-
us darzalex sale forecast seem reason model us darzalex sale
yr/yr increas ww sale growth us forecast slighlti
extrapol im sale gener seem reason continu forecast
ww sale genmab estim darzalex recent approv front-lin
use us base maia data affirm drug statu part backbon
treatment multipl myeloma mm help maintain strong growth momentum anticip
approv darzalex front-lin use transplant elig patient later year also contribut
continu solid growth accord brandimpact darzalex held share share
line mm market may repres product respect segment figur
darzalex held overal market share survey reflect share front-lin use
maia approv
potenti modest upsid us imbruvica estim forecast us imbruvica revenu
impli end-us sale forecast seem somewhat conserv
compar extrapol im sale closer impli revenu
chang forecast given modest magnitud potenti upsid global basi
imbruvica forecast translat revenu direct
consist abbv guidanc imbruvica revenu approach rx perspect
roll imbruvica volum grew weekli approach
figur call note imbruvica remain market leader cll across line
therapi new patient share front-lin set
lower us invokana sale forecast rx declin share loss continu
reduc us invokana sale estim yr/yr base
extrapol im sale invokana franchis volum fell
vs volum declin like due neg chang drug formulari statu
year figur im data first three week june also show yr/yr rx volum declin
figur invokana franchis nrx share class also fell dec
may seem posit efficaci find credenc renal outcom trial report
help stem sale declin competitor boehring ingelheim lli jardian
franchis remain leader categori nrx share increas
may nrx volum grow ytd figur recal jardianc empa-reg
lower cardiovascular risk without
outcom trial show drug
amputation/fractur risk categori nrx growth averag ytd vs growth
increas us zytiga sale estim us gener zytiga competit began decemb
impact appear benign expect extrapol zytiga im sale
better better forecast addit discounts/reb
accrual may affect final number estim seem conserv increas us
zytiga sale estim yr/yr declin vs declin zytiga held
abirateron share may share februari still well
expect addit jnj gener zytiga perform well share ahead
myl apotex share
erleada uptak climb measur pace nearli month sinc launch
erleada us sale annual base may im sale annual im sale
six month ago monthli erleada trx nrx volum increas slowli ytd
estim us erleada sale seem reason base extrapol im sale data
chang xarelto forecast like increas discounting/reb forecast
xarelto sale yr/yr declin extrapol im sale impli wide rang
chang forecast believ rebating/discount play increasingli
import role competit market likelihood increas discounting/reb make
histor reported/im sale ratio less reliabl forecast addit report two consecut
quarter xarelto sale declin part due prior period price adjust make us
bit cautiou price adjust monthli xarelto trx nrx volum show
yr/yr growth apr/may consist trend past year figur
overal novel oral anticoagul noac market growth may eliqui maintain lead
among noac share m/m follow xarelto share
m/m past year xarelto lost share eliqui gain nearli share figur
noac account oral anticoagul nrx end figur
oct fda approv xarelto use cad/pad coronari arteri disease/peripher arteri
diseas im sale trend suggest xarelto cad/pad ad franchis
us invega sustenna/trinza im sale well trend forecast us sale
growth yr/yr well extrapol im sale rang howev
note apr/may im sale jnj long-act inject atyp laia franchis sustenna trinza
risperd consta yr/yr inconsist recent histor trend larg
double-digit growth franchis figur unclear us chang im
calcul data sourc could affect apr/may data chang
forecast given uncertainti data us laia market maintain lead
franchis nrx market share past month ostuka abilifi maintena
hold share yr/yr aristada share yr/yr figur
chang us stelara sale forecast forecast us stelara sale
yr/yr growth within extrapol im sale rang chang forecast
sale affect prior period price adjust thu creat uncertainti around
price adjust and/or rebating/discount chang stelara im sale grew apr/may
growth suggest modest deceler perhap due strong uptak tremfya
figur stelara trx volum specialti continu show crohn key growth driver
growth volum written gastroenterolog specialist past year partli
off-set rheumatologist dermatologist stelara
stelara approv ulcer coliti help maintain growth momentum
increas us tremfya sale forecast rais us tremfya sale
base extrapol im sale rang report sale track
rel consist im sale sinc launch nearli year market tremfya im sale
annual base apr/may data comparison nv cosentyx lli taltz sale
annual close time post-launch current cosentyx im sale annual
taltz im sale annual weekli tremfya volum track well
ahead stelara remain behind cosentyx taltz time post-launch figur
continu see tremfya import growth driver despit cannib stelara
sale sun pharma ilumya continu see littl traction market nearli year post launch
rais us simponi/aria sale estim increas us simponi/aria sale
forecast base extrapol im sale rang forecast
impli growth yr/yr deceler due tougher comp apr/may simponi
im sale flattish aria im sale grew togeth drive franchis growth
repres deceler mostli low doubl digit growth franchis recent quarter figur
rais us tracleer sale forecast us gener tracleer competit began mid-jun later
expect increas us tracleer sale forecast
yr/yr consist extrapol im sale rest us pah peripher arteri
hypertens franchis forecast us opsumit sale uptravi sale
seem consist extrapol im sale rang
respect figur note ratio report im sale vari quarter quarter
analysi independ arriv secur llc basi data
inform im respons relianc recipi either data analys
compris mostli pfe/celltrion inflectra
 us split im health incorpor nation sale perspect compani report secur llc estim sale estim base commentari im data forecast us imbruvica sale assum record end-us sale report consist third month perform prior quarter assum june im sale repres im sale remicadebiosimilar remicad medic technolog
figur darzalex hold posit line multipl myeloma market
figur darzalex maintain lead line multipl myeloma market
follow chang imbruvica ndc nation drug code im report doubl count rx
one distributor late march continu part year
figur invokana franchis continu lose share
growthmonthli trxtrx volumetrx rx y/i present canva data ada meet -posit efficaci safeti trade-off strengthen warn risk acut kidney add black box warn leg foot amput market share invokana invokamet jardianc synjardi glyxambi azn farxiga xigduo xr medic technolog
figur zytiga erleada monthli volum growth trend
new oral anticoagul includ pradaxa xarelto eliqui savaysa
 nrxnrxoral anticoagulantsnew oral anticoagul new oral anticoagul xarelto spaf approvedeliqui spaf approvedeliqui dvt prevent approvedsavaysa spaf approvedeliqui dvt treatment approvedxarelto dvt treatment growthim sale sustenna trinza consta sale yoy im sale growthsustenna launch aug launch jun medic technolog
figur atln opsumit im sale maintain growth momentum
figur atln tracleer im sale declin
figur atln uptravi im sale remain solid launch trajectori
price target nc
price target impli cash ep base sum-of-the-part
analysi risk includ delay pipelin product unexpect delay deal integr unexpect
deterior industri
expect growth slow due multipl headwind see growth re-acceler
johnson johnson world comprehens broadli base healthcar compani
consum pharmaceut medic devic market medic devic segment consist primarili
product cardiovascular orthoped surgic vision compani report sale
year-over-year organ basi
